← ANALYST RATINGS · TIPRANKS
Mesa Laboratories (MLAB): analyst forecast and price target
Analyst consensus
0 Buy0 Hold0 Sell
Ratings of 0 analysts in the last 3 months12-month forecast
Based on 0 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $122.
Analyst ratings 1
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - SpecialtiesxAI Grok-4 | TipRanks - xAI | $152 → $157+3.3% | Buy | +28.2% | Reiterated | 06.10.26on TipRanks 01:05 | — | |
| AI DeepSeek Medical - SpecialtiesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $149 → $154+3.4% | Hold | +25.7% | Reiterated | 06.10.26on TipRanks 01:05 | — | |
| AI OpenAI Medical - SpecialtiesOpenAI 5.2 | TipRanks - OpenAI | $149 → $154+3.4% | Hold | +25.7% | Reiterated | 06.10.26on TipRanks 01:05 | — | |
| AI Anthropic Medical - SpecialtiesAnthropic Opus-4.6 | TipRanks - Anthropic | $143 → $148+3.5% | Hold | +20.8% | Reiterated | 06.10.26on TipRanks 01:05 | — | |
| AI Google Medical - SpecialtiesGemini 3.1Pro | TipRanks - Google | $151 → $156+3.3% | Buy | +27.4% | Upgrade | 06.10.26on TipRanks 01:05 | — | |
| AI PerPlexity Medical - SpecialtiesPerPlexity SonarPro | TipRanks - PerPlexity | $148 → $153+3.4% | Hold | +24.9% | Reiterated | 06.10.26on TipRanks 01:05 | — | |
| AI xAi Medical - SpecialtiesxAI Grok-4 | TipRanks - xAI | $141 → $152+7.8% | Buy | +24.1% | Reiterated | 25.09.26on TipRanks 08:06 | — | |
| AI DeepSeek Medical - SpecialtiesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $138 → $149+8.0% | Hold | +21.7% | Reiterated | 25.09.26on TipRanks 08:06 | — | |
| AI OpenAI Medical - SpecialtiesOpenAI 5.2 | TipRanks - OpenAI | $138 → $149+8.0% | Hold | +21.7% | Reiterated | 25.09.26on TipRanks 08:06 | — | |
| AI Anthropic Medical - SpecialtiesAnthropic Opus-4.6 | TipRanks - Anthropic | $133 → $143+7.5% | Hold | +16.8% | Reiterated | 25.09.26on TipRanks 08:06 | — | |
| AI Google Medical - SpecialtiesGemini 3.1Pro | TipRanks - Google | $141 → $151+7.1% | Buy | +23.3% | Upgrade | 25.09.26on TipRanks 08:06 | — | |
| AI PerPlexity Medical - SpecialtiesPerPlexity SonarPro | TipRanks - PerPlexity | $137 → $148+8.0% | Hold | +20.8% | Reiterated | 25.09.26on TipRanks 08:06 | — | |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $115 | Buy | −6.1% | Reiterated | 11.03.26on TipRanks 09:25 | +10.2%next day −1.9% · 5 days +1.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Mesa Laboratories
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q2 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.29 (from $2.24 to $2.34). Last quarter: $2.68.
Sales
Next quarter’s sales estimate — $62M (from $61M to $64M). Last quarter: $60M.
Best top-analyst consensus in the sector · Technology
About Mesa Laboratories
- CEO: Siddhartha C. Kadia
- Employees: 717
- 12100 West Sixth Avenue, Lakewood, CO, 80228, US
- www.mesalabs.com
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Data from the stock’s TipRanks forecast page, read 67 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗